logo

ATXS(Delisted)

Astria Therapeutics·NASDAQ
--
--(--)
6.71 / 10
Outperform

ATXS demonstrates solid revenue momentum with Total Operating Revenue up 78.69% YoY and Operating Revenue up 92.88% YoY, both in the top half of their quartiles. However, the Annualized Return on Equity is deeply negative at -47.49%, and key efficiency metrics—Days Sales Outstanding (3297.17) and Inventory Turnover Ratio (47.95)—signal operational inefficiencies. The Revenue-MV factor is slightly negative (-4.53), while PB-ROE (0.46) and Asset-MV (-0.51) are neutral. These mixed signals yield a fundamental score of 6.71/10, justifying an Outperform rating but with caveats on profitability and working capital management.

Fundamental(6.71)SentimentTechnical

Analysis Checks(7/10)

Revenue-MV
Value-4.53
Score3/3
Weight38.60%
1M Return9.55%
Annualized return on equity (%)
Value-47.49
Score1/3
Weight-4.36%
1M Return-1.46%
Total operating revenue (YoY growth rate %)
Value78.69
Score3/3
Weight2.31%
1M Return0.71%
Days sales outstanding
Value3297.17
Score2/3
Weight-4.81%
1M Return-1.61%
Inventory turnover ratio
Value47.95
Score2/3
Weight-3.82%
1M Return-1.29%
PB-ROE
Value0.46
Score1/3
Weight32.54%
1M Return7.97%
Income tax / Total profit (%)
Value-5.76
Score0/3
Weight-6.12%
1M Return-2.09%
Operating revenue (YoY growth rate %)
Value92.88
Score2/3
Weight0.27%
1M Return0.08%
Cost of sales ratio (%)
Value70.60
Score2/3
Weight-4.18%
1M Return-1.43%
Asset-MV
Value-0.51
Score3/3
Weight49.57%
1M Return10.37%
Is ATXS undervalued or overvalued?
  • ATXS scores 6.71/10 on fundamentals and holds a Discounted valuation at present. Backed by its -35.62% ROE, 0.00% net margin, 0.00 P/E ratio, 0.00 P/B ratio, and 1.83% earnings growth, these metrics solidify its Outperform investment rating.